BCL2 and neoplasm: The first attempt to target BCL2 using the antisense oligonucleotide oblimersen (G3139) demonstrated limited clinical efficacy in chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) and B cell non-Hodgkin lymphoma (B-NHL) [4–6] and subsequent preclinical studies cast doubt over its capacity to effectively target BCL2 in tumor cells [7].